"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
At present, there are no known contraindications to the use of OCUCOAT (hydroxypropylmethylcellulose) when used as recommended.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/8/2004
Additional Ocucoat Information
Report Problems to the Food and Drug Administration
Find out what women really need.